European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable...

NEW YORK, Aug. 12, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to
http://www.reportlinker.com/p01595154/European-Nuclear-Medicine-/-Radiopharmaceuticals-Market-[SPECT/PET-Radioisotopes-Technetium-F-18]-[Beta/Alpha-Radiation-Therapy-I131-Y-90]-[Applications-Cancer/Oncology-Cardiac]--Stable-Isotopes-Deuterium-C-13---Global-Trends--Forecast-to.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017]

The European radioisotopes market was valued at $1.1 billion in 2012 and is poised to reach $1.6 billion in 2017 at a CAGR of 6.8%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, and other developed regions between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France in 2018 is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

Germany is the largest consumer market for radiopharmaceuticals in the Europe. There are only 5 major reactors in the world and most of the countries are completely dependent on the productions from those reactors. A few countries such as Poland, Australia, Argentina, and South Africa have started producing Tc-99m at their own reactors in a small scale. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Covidien, Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Siemens Healthcare (PETNET) (Germany).

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Isotec (Sigma Aldrich) (U.S.) - in 2012; they jointly contributed more than 50% to the European revenue.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the European scenario.

European Radiopharmaceuticals Market

Diagnostic
SPECT
Tc-99m
Tl-201
Ga-67
I-123
Others
PET
F-18
Rb-82
Others
Therapy
Beta emitters
I-131
Sm-153
Re-186
Y-90
Lu-177
Others
Alpha emitters
Brachytherapy
Cs-131
I-125
Pd-103
Ir-192
Others

European Enriched Stable Isotopes Market

Deuterium
Oxygen-18
Carbon-13
Nitrogen-15
Others

Radiopharmaceutical and Stable Isotope Markets, By Geography

France
Germany
Italy
Spain
U.K.
Russia
RoE

1 INTRODUCTION 25
1.1 KEY TAKE-AWAYS 25
1.2 REPORT DESCRIPTION 25
1.3 MARKETS COVERED 27
1.4 STAKEHOLDERS 28
1.5 RESEARCH METHODOLOGY 29
1.5.1 MARKET SIZE 29
1.5.2 MARKET SHARE 30
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 30
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 30
1.5.5 ASSUMPTIONS 31

2 EXECUTIVE SUMMARY 32

3 MARKET OVERVIEW 37
3.1 INTRODUCTION 38
3.2 DEFINITION OF RADIOPHARMACEUTICALS 38
3.3 EVOLUTION 39
3.4 MARKET SEGMENTATION 40
3.4.1 RADIOPHARMACEUTICALS 40
3.4.2 STABLE ISOTOPES 41
3.5 MARKET DYNAMICS 42
3.5.1 DRIVERS 43
3.5.1.1 Increasing incidence of cancer and cardiac ailments boosts the demand for radiopharmaceuticals 43
3.5.1.2 Increasing use of SPECT and PET scans results in rise of radiopharmaceutical usage 43
3.5.1.3 Rising awareness of radiopharmaceuticals to spur growth 44
3.5.1.4 Ready availability of radiopharmaceuticals from cyclotrons to goad the growth 44
3.5.2 RESTRAINTS 44
3.5.2.1 Shorter half-life of radiopharmaceuticals restricts the usage 44
3.5.2.2 High capital to limit the buying of scanners 45
3.5.2.3 Stringent regulatory guidelines and GMP to negatively impact growth 45
3.5.2.4 Competition from conventional diagnostic procedures 46
3.5.3 OPPORTUNITIES 46
3.5.3.1 Potential radioisotopes in the pipeline 46
3.5.3.2 Alpha radioimmunotherapy-based targeted cancer treatment 47
3.5.3.3 Alternative diagnostic radiopharmaceutical solutions 47
3.5.3.4 Cyclotron based production 48
3.5.3.5 Neurological applications 48
3.5.4 THREAT 48
3.5.4.1 Shutdown of nuclear reactors to impact production of radioisotopes 48
3.6 WINNING IMPERATIVES 49
3.6.1 INVESTMENTS ON NEW RADIOISOTOPES AND NOVEL APPLICATIONS 49
3.6.2 SHIFT TOWARDS LEU-BASED MO-99 PRODUCTION 49
3.7 BURNING ISSUES 50
3.7.1 HIGH COST OF PET CAMERAS 50
3.7.2 SHORTAGE IN SUPPLY OF TECHNETIUM-99M 50
3.8 REGULATORY AFFAIRS 51
3.8.1 GERMANY 51
3.8.1.1 German Medicinal Products Act (AMG) 51
3.8.1.2 Amendments to the German Medicinal Products Act (AMG) 52
3.8.2 FRANCE 52
3.8.2.1 Agence Française de la Securité Sanitaire des Produits de la Santé (AFSSAPS) 52
3.8.3 U.K. 53
3.8.3.1 The Medicines and Healthcare Products Regulatory Agency (MHRA) 53
3.8.4 SPAIN 53
3.8.5 ITALY 54
3.8.5.1 The Italian Pharmaceutical Agency (AIFA) 54
3.8.6 RUSSIA 54
3.8.6.1 The Federal Law 54
3.9 MARKET SHARE ANALYSIS 55
3.9.1 EUROPEAN RADIOPHARMACEUTICALS MARKET 55
3.9.1.1 Germany 57
3.9.1.2 France 58
3.9.1.3 Italy 59
3.9.1.4 Spain 60
3.9.1.5 U.K. 61
3.9.1.6 Switzerland 62
3.9.1.7 Russia 63
3.9.2 ENRICHED STABLE ISOTOPE MARKET 64

4 EUROPEAN RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 65
4.1 INTRODUCTION 66
4.2 DIAGNOSTIC MARKET 66
4.2.1 OPPORTUNITY MATRIX 67
4.2.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) RADIOPHARMACEUTICALS 69
4.2.2.1 Technetium-99m (Tc-99m) 71
4.2.2.1.1 Tc-99m to decide growth trend of SPECT radioisotopes 73
4.2.2.1.2 Factors affecting Technetium-99m market 75
4.2.2.1.2.1 Technetium can combine with 31 different carrier molecules 75
4.2.2.1.2.2 Lack of availability of technetium 75
4.2.2.2 Thallium-201 (Tl-201) 75
4.2.2.2.1 Tl-201 is a potential substitute for Tc-99m 76
4.2.2.3 Gallium-67 (Ga-67) 77
4.2.2.3.1 Fluorine-18 (PET) might seize Ga-67 (SPECT) market share in the near future 77
4.2.2.4 Iodine (I-123) 78
4.2.2.5 Others 80
4.2.3 POSITRON-EMISSION TOMOGRAPHY (PET) RADIOPHARMACEUTICALS 82
4.2.3.1 Fluorine-18 84
4.2.3.1.1 FDG 84
4.2.3.1.2 Florbetapir 85
4.2.3.1.3 Factors affecting Fluorine-18 market 86
4.2.3.1.3.1 Rise in PET procedures increases demand
for FDG 86
4.2.3.1.3.2 High generation costs of FDG 87
4.2.3.1.3.3 Need for speedy & efficient transportation 87
4.2.3.2 Rubidium-82 (Rb-82) 87
4.2.3.3 Others 88
4.3 THERAPEUTIC ISOTOPES 90
4.3.1 OPPORTUNITY MATRIX 91
4.3.2 BETA EMITTERS 92
4.3.2.1 Iodine-131 (I-131) 94
4.3.2.2 Yttrium-90 (Y-90) 96
4.3.2.2.1 Y-90 market influenced by popularity of Nordion's TheraSphere 96
4.3.2.3 Samarium-153 (Sm-153) 97
4.3.2.4 Rhenium-186 (Re-186) 99
4.3.2.5 Lutetium-177 (Lu-177) 100
4.3.2.5.1 Lu-177 is a potential treatment option for neuroendocrine cancer 101
4.3.2.6 Others 102
4.3.2.6.1 Re-188 and P-33 are notable promising isotope 102
4.3.3 ALPHA EMITTERS 103
4.3.3.1 Radium-223 (Ra-223) & Alpharadin 104
4.3.3.1.1 Successful completion of Phase III trials in men with bone metastases from CRPC 106
4.3.3.1.2 First in-class alpha pharmaceutical 106
4.3.3.1.3 Alpharadin is advantageous over Taxotere, beta-therapy and brachytherapy 106
4.3.3.1.4 Success of Alpharadin 107
4.3.3.1.5 Porter's five forces analysis 107
4.3.3.1.6 SWOT analysis 109
4.3.3.2 Actinium-225 (Ac-225) 110
4.3.3.3 Lead-212 (Pb-212)/Bismuth-212 (Bi-212) 110
4.3.3.4 Astatine-211 (At-211) 110
4.3.3.5 Radium-224 (Ra-224) 110
4.3.3.6 Thorium-227 (Th-227) 111
4.3.4 BRACHYTHERAPY 111
4.3.4.1 Cesium-131 115
4.3.4.2 Iodine-125 116
4.3.4.3 Palladium-103 117
4.3.4.4 Iridium-192 118
4.3.4.5 Others 119

5 EUROPEAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION/INDICATION 121
5.1 INTRODUCTION 122
5.2 DIAGNOSTIC APPLICATION 122
5.2.1 SPECT 123
5.2.1.1 Cardiology 125
5.2.1.2 Lymphoma 126
5.2.1.3 Thyroid 127
5.2.1.4 Neurology 129
5.2.1.4.1 Alzheimer's, dementia, and Parkinson's disease driving growth of the neurology SPECT market 129
5.2.1.5 Others 130
5.2.2 PET 131
5.2.2.1 Oncology 132
5.2.2.1.1 FDG F-18 has become a gold standard for oncology diagnosis using PET scan 133
5.2.2.2 Cardiology 134
5.2.2.3 Neurology 135
5.2.2.4 Others 136
5.3 THERAPEUTIC APPLICATION 138
5.3.1 THYROID 139
5.3.2 BONE METASTASIS 141
5.3.3 LYMPHOMA 142
5.3.4 ENDOCRINE TUMORS 143
5.3.5 OTHERS 145

6 EUROPEAN ENRICHED STABLE ISOTOPES MARKET 146
6.1 INTRODUCTION 147
6.2 MARKET OVERVIEW 148
6.3 MARKET DYNAMICS 149
6.3.1 DRIVERS 149
6.3.1.1 Stable isotopes are natural in origin & hence safe 149
6.3.1.2 Proteomics & system biology, major factors to boost the growth of stables 149
6.3.1.3 Medical applications propel stable isotopes market growth 149
6.3.2 RESTRAINTS 150
6.3.2.1 Harmful effects of high doses of stable isotopes affect market growth 150
6.3.2.2 High cost of stables isotope 150
6.4 ENRICHED STABLES MARKET, BY ISOTOPE 151
6.4.1 DEUTERIUM & O-18 ARE PROMISING ISOTOPES 152
6.4.2 CARBON-13 154
6.4.3 DEUTERIUM 155
6.4.4 OXYGEN-18 156
6.4.5 NITROGEN-15 157
6.4.6 OTHER STABLE ISOTOPES 158
6.5 ENRICHED STABLES MARKET, BY APPLICATION 159
6.5.1 DIAGNOSTIC & THERAPY 159
6.5.2 RESEARCH 161
6.5.3 PHARMACEUTICAL 162
6.5.4 INDUSTRIAL SECTOR 163

7 GEOGRAPHIC ANALYSIS 165
7.1 INTRODUCTION 165
7.2 GERMANY 166
7.3 FRANCE 172
7.4 U.K. 177
7.5 SPAIN 182
7.6 ITALY 187
7.7 RUSSIA 192
7.8 REST OF EUROPE 197

8 COMPETITIVE LANDSCAPE 203
8.1 INTRODUCTION 203
8.2 MERGERS & ACQUISITIONS 204
8.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS &
JOINT VENTURES 205
8.4 NEW PRODUCTS LAUNCH 208
8.5 EXPANSIONS 210
8.6 OTHER DEVELOPMENTS 211

9 COMPANY PROFILES 215
(Overview, Financials, Products & Services, Strategy, & Developments)*
9.1 COMPANIES 215
9.1.1 BRACCO IMAGING S.P.A. 215
9.1.2 CAMBRIDGE ISOTOPE LABORATORIES, INC. 218
9.1.3 CARDINAL HEALTH, INC. 222
9.1.4 COVIDIEN, PLC 228
9.1.5 ECZACIBASI-MONROL 233
9.1.6 FUJIFILM HOLDINGS CORPORATION 235
9.1.7 GE HEALTHCARE
(SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 240
9.1.8 IBA GROUP 246
9.1.9 ISOTEC, INC. (SIGMA-ALDRICH) 253
9.1.10 LANTHEUS MEDICAL IMAGING, INC. 257
9.1.11 NORDION, INC. 264
9.1.12 NTP RADIOISOTOPES (PTY), LTD. 271
9.1.13 PETNET SOLUTIONS, INC. (A SUBSIDIARY OF SIEMENS MEDICAL SOLUTIONS USA, INC.) 274
9.1.14 TAIYO NIPPON SANSO CORPORATION 279
9.1.15 ROTEM INDUSTRIES, LTD., INC. 283
9.1.16 URENCO LIMITED 285
9.2 INSTITUTES 289
9.2.1 AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO) 289
9.2.2 INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE 292
9.2.3 INSTITUTE OF ISOTOPES CO., LTD. 294
9.2.4 INSTITUTE OF RADIOELEMENT (IRE) 297
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

LIST OF TABLES

TABLE 1 EUROPE: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 33
TABLE 2 EUROPE: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 67
TABLE 3 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 70
TABLE 4 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 71
TABLE 5 INDICATIONS DIAGNOSED BY TC-99M 72
TABLE 6 EUROPE: TC-99M MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 74
TABLE 7 EUROPE: TL-201 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 76
TABLE 8 EUROPE: GA-67 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 78
TABLE 9 EUROPE: I-123 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 79
TABLE 10 EUROPE: OTHER RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 81
TABLE 11 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 83
TABLE 12 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 84
TABLE 13 EUROPE: F-18 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 86
TABLE 14 EUROPE: RB-82 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 88
TABLE 15 EUROPE: OTHER PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 89
TABLE 16 EUROPE: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 90
TABLE 17 EUROPE: BETA EMITTER RADIOPHARMACEUTICALS MARKET,
BY ISOTOPE, 2010 – 2017 ($MILLION) 93
TABLE 18 EUROPE: BETA EMITTER RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 94
TABLE 19 EUROPE: I-131 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 95
TABLE 20 EUROPE: Y-90 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 97
TABLE 21 EUROPE: SM-153 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 98
TABLE 22 EUROPE: RE-186 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 100
TABLE 23 EUROPE: LU-177 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 101
TABLE 24 EUROPE: OTHER BETA EMITTERS MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 103
TABLE 25 ALPHA EMITTERS VS BETA EMITTERS 104
TABLE 26 RADIOPHARMACEUTICALS CHARACTERISTICS & DOSE DELIVERY OVER TIME 112
TABLE 27 EUROPE: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 114
TABLE 28 EUROPE: BRACHYTHERAPY MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 115
TABLE 29 EUROPE: CS-131 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 116
TABLE 30 EUROPE: I-125 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 117
TABLE 31 EUROPE: PD-103 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 118
TABLE 32 EUROPE: IR-192 MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 119
TABLE 33 EUROPE: OTHER BRACHYTHERAPY MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 120
TABLE 34 EUROPE: SPECT APPLICATION MARKET, 2010 – 2017 ($MILLION) 124
TABLE 35 EUROPE: CARDIOLOGY SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 125
TABLE 36 EUROPE: LYMPHOMA SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 127
TABLE 37 EUROPE: THYROID SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 128
TABLE 38 EUROPE: NEUROLOGY SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 130
TABLE 39 EUROPE: OTHER SPECT APPLICATIONS MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 131
TABLE 40 EUROPE: PET APPLICATION MARKET, 2010 – 2017 ($MILLION) 132
TABLE 41 EUROPE: ONCOLOGY PET MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 133
TABLE 42 EUROPE: CARDIOLOGY PET MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 134
TABLE 43 EUROPE: NEUROLOGY PET MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 136
TABLE 44 EUROPE: OTHER PET APPLICATIONS MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 137
TABLE 45 EUROPE: RADIOPHARMACEUTICAL THERAPEUTIC APPLICATION MARKET, 2010 – 2017 ($MILLION) 138
TABLE 46 EUROPE: RADIOPHARMACEUTICAL THERAPEUTIC APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 139
TABLE 47 EUROPE: RADIOPHARMACEUTICAL THYROID APPLICATION MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 140
TABLE 48 EUROPE: RADIOPHARMACEUTICAL BONE METASTASIS APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 142
TABLE 49 EUROPE: RADIOPHARMACEUTICAL LYMPHOMA APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 143
TABLE 50 EUROPE: RADIOPHARMACEUTICAL ENDOCRINE APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 144
TABLE 51 EUROPE: RADIOPHARMACEUTICAL OTHER APPLICATIONS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 145
TABLE 52 EUROPE: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 151
TABLE 53 EUROPE: STABLE ISOTOPE MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 153
TABLE 54 EUROPE: CARBON STABLE ISOTOPE MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 154
TABLE 55 EUROPE: DEUTERIUM STABLE ISOTOPE MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 155
TABLE 56 EUROPE: OXYGEN STABLE ISOTOPE MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 156
TABLE 57 EUROPE: NITROGEN STABLE ISOTOPE MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 157
TABLE 58 EUROPE: OTHER STABLE ISOTOPE MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 158
TABLE 59 EUROPE: ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 159
TABLE 60 EUROPE: STABLE ISOTOPES MARKET FOR DIAGNOSTIC & THERAPEUTIC APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 160
TABLE 61 EUROPE: STABLE ISOTOPES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 162
TABLE 62 EUROPE: STABLE ISOTOPES MARKET FOR PHARMACEUTICAL APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 163
TABLE 63 EUROPE: STABLE ISOTOPES MARKET FOR INDUSTRIAL APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 164
TABLE 64 GERMANY: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 168
TABLE 65 GERMANY: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 169
TABLE 66 GERMANY: RADIOPHARMACEUTICAL MARKET, BY THERAPY,|
2010 – 2017 ($MILLION) 169
TABLE 67 GERMANY: BETA EMITTER MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 170
TABLE 68 GERMANY: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 171
TABLE 69 GERMANY: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 172
TABLE 70 FRANCE: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 173
TABLE 71 FRANCE: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 174
TABLE 72 FRANCE: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 174
TABLE 73 FRANCE: BETA EMITTER MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 175
TABLE 74 FRANCE: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 176
TABLE 75 FRANCE: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 177
TABLE 76 U.K.: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 178
TABLE 77 U.K.: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 179
TABLE 78 U.K.: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 179
TABLE 79 U.K.: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 180
TABLE 80 U.K.: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 181
TABLE 81 U.K.: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 182
TABLE 82 SPAIN: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 183
TABLE 83 SPAIN: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 184
TABLE 84 SPAIN: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 184
TABLE 85 SPAIN: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 185
TABLE 86 SPAIN: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 186
TABLE 87 SPAIN: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 187
TABLE 88 ITALY: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 188
TABLE 89 ITALY: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 189
TABLE 90 ITALY: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 189
TABLE 91 ITALY: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 190
TABLE 92 ITALY: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 191
TABLE 93 ITALY: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 192
TABLE 94 RUSSIA: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 193
TABLE 95 RUSSIA: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 194
TABLE 96 RUSSIA: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 194
TABLE 97 RUSSIA: BETA EMITTER MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 195
TABLE 98 RUSSIA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 196
TABLE 99 RUSSIA: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 197
TABLE 100 ROE: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 198
TABLE 101 ROE: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 199
TABLE 102 ROE: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 199
TABLE 103 ROE: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 200
TABLE 104 ROE: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 201
TABLE 105 ROE: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 202
TABLE 106 MERGERS & ACQUISITIONS, 2010 – 2012 204
TABLE 107 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS &
JOINT VENTURES, 2010 – 2013 205
TABLE 108 NEW PRODUCTS LAUNCH, 2010 –2013 208
TABLE 109 EXPANSIONS, 2010 –2012 210
TABLE 110 OTHER DEVELOPMENTS, 2010 – 2012 211
TABLE 111 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE,
BY SEGMENT, 2010 – 2012 ($MILLION) 219
TABLE 112 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE,
BY GEOGRAPHY, 2010 – 2012 ($MILLION) 220
TABLE 113 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 223
TABLE 114 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 224
TABLE 115 COVIDIEN, PLC: TOTAL REVENUE AND R&D EXPENDITURE,
2010 – 2012 ($MILLION) 229
TABLE 116 COVIDIEN, PLC: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 229
TABLE 117 COVIDIEN, PLC: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 231
TABLE 118 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 237
TABLE 119 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 237
TABLE 120 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY SEGMENT,
2009 – 2011 ($BILLION) 241
TABLE 121 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($BILLION) 242
TABLE 122 IBA GROUP: MARKET REVENUE, BY SEGMENT,
2009 – 2011 ($MILLION) 247
TABLE 123 IBA GROUP: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 248
TABLE 124 ISOTEC INC.: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 254
TABLE 125 ISOTEC INC.: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 255
TABLE 126 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 259
TABLE 127 LANTHEUS: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 259
TABLE 128 NORDION, INC.: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 266
TABLE 129 NORDION, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2017 266
TABLE 130 SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES,
2010 – 2012 ($MILLION) 275
TABLE 131 SIEMENS AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION) 275
TABLE 132 SIEMENS AG: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 276
TABLE 133 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 281

LIST OF FIGURES

FIGURE 1 EUROPE: RADIOPHARMACEUTICALS MARKET, BY SEGMENT,
2010 – 2017 33
FIGURE 2 EUROPE: RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2012 ($MILLION) 34
FIGURE 3 EUROPE: STABLE ISOTOPES MARKET, 2012 – 2017 ($MILLION) 36
FIGURE 4 EVOLUTION OF RADIOPHARMACEUTICALS 39
FIGURE 5 RADIOPHARMACEUTICALS MARKET SEGMENTATION 40
FIGURE 6 ENRICHED STABLE ISOTOPES MARKET SEGMENTATION 41
FIGURE 7 MARKET DYNAMICS 42
FIGURE 8 EUROPEAN RADIOPHARMACEUTICALS: MARKET SHARE ANALYSIS,
BY KEY PLAYERS, 2012 56
FIGURE 9 GERMANY: RADIOPHARMACEUTICALS MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 57
FIGURE 10 FRANCE: RADIOPHARMACEUTICALS MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 58
FIGURE 11 ITALY: RADIOPHARMACEUTICALS MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 59
FIGURE 12 SPAIN: RADIOPHARMACEUTICALS MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 60
FIGURE 13 U.K.: RADIOPHARMACEUTICALS MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 61
FIGURE 14 SWITZERLAND: RADIOPHARMACEUTICALS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2012 62
FIGURE 15 EUROPEAN ENRICHED STABLE ISOTOPE: MARKET SHARE ANALYSIS,
BY KEY PLAYERS, 2012 64
FIGURE 16 OPPORTUNITY MATRIX: EUROPEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET (2012) 68
FIGURE 17 SPECT RADIOPHARMACEUTICALS MARKET SHARE (2012) 69
FIGURE 18 PET RADIOPHARMACEUTICALS MARKET SHARE(2012) 82
FIGURE 19 OPPORTUNITY MATRIX: EUROPEAN THERAPEUTIC RADIOPHARMACEUTICALS MARKET (2012) 91
FIGURE 20 RA-223 DECAY CHAIN 105
FIGURE 21 PORTER'S FIVE FORCES ANALYSIS FOR ALPHARADIN 108
FIGURE 22 SWOT ANALYSIS OF ALPHARADIN 109
FIGURE 23 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET, BY INDICATION (2012) 123
FIGURE 24 KEY GROWTH STRATEGIES, 2010 –2013 203
FIGURE 25 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION) 219
FIGURE 26 CARDINAL HEALTH, INC.: TOTAL REVENUE, 2010 – 2012 ($BILLION) 223
FIGURE 27 COVIDIEN, PLC: RADIOPHARMACEUTICALS REVENUE,
2010 – 2012 ($BILLION) 230
FIGURE 28 FUJIFILM HOLDINGS CORP: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($BILLION) 236
FIGURE 29 GENERAL ELECTRIC COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($BILLION) 241
FIGURE 30 IBA GROUP: TOTAL MARKET REVENUE, 2009 – 2011 ($MILLION) 247
FIGURE 31 ISOTEC INC.: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($BILLION) 254
FIGURE 32 LANTHEUS: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($MILLION) 258
FIGURE 33 NORDION, INC.: TOTAL MARKET REVENUE, 2010 – 2012 ($BILLION) 265
FIGURE 34 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($BILLION) 280
FIGURE 35 URENCO LIMITED: TOTAL MARKET REVENUE, 2009 – 2011 ($BILLION) 286

To order this report:
Medical_Imaging Industry: European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to

__________________________
Contact Clare: clare@reportlinker.com  
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker